Brief: Tcr2 Therapeutics QTRLY Loss Per Share $16.22

TCR2 Therapeutics

01/04/2019 12:35

April 1 (Reuters) - Tcr2 Therapeutics Inc  TCRR.O :
    * TCR2 THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2018
FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
    * TCR2 THERAPEUTICS - ENDED 2018 WITH $123.2 MILLION IN
CASH, CASH
EQUIVALENTS, AND INVESTMENTS COMPARED TO $19.8 MILLION AS OF
DECEMBER 31, 2017.
    * TCR2 THERAPEUTICS - QTRLY LOSS PER SHARE $16.22

Source text for Eikon:  ID:nPn2RLsvfa 
Further company coverage:  TCRR.O 

 ((Reuters.Briefs@thomsonreuters.com;))